Tralokinumab-Associated Paradoxical Psoriasis: A Systematic Review of Clinical Phenotypes, Latency, and Treatment Outcomes

Background: Tralokinumab is a fully human IgG4 monoclonal antibody that neutralises interleukin (IL)-13 and is approved for moderate- to-severe atopic dermatitis (AD). Psoriasis during IL-4/IL-13 receptor blockade with dupilumab is well described. During selective IL-13 neutralisation it has been reported only sporadically, and no systematic synthesis exists. Objective: To identify and characterise all reported psoriasis and psoriasiform eruptions during tralokinumab therapy, with emphasis on clinical phenotype, latency, management, outcomes and strength of causal evidence. Methods: This review followed PRISMA 2020 and PRISMA-S. We searched Europe PMC (three strategies, one of them full-text), PubMed/MEDLINE, Crossref and ClinicalTrials.gov from inception to 30 September 2026. These searches were supplemented by forward and backward citation searching, automated full-text keyword screening of 371 open-access articles, and review of regulatory labelling. Embase, Scopus and Web of Science were not accessible. Human studies of any design reporting psoriasis or a psoriasiform eruption in tralokinumab-exposed patients were eligible. Events were classified as new-onset psoriasis (Category A), relapse or exacerbation of pre-existing psoriasis (Category B), psoriasiform eruption without confirmed psoriasis (Category C) or diagnostic uncertainty (Category D). Quality was appraised with design-specific JBI checklists, and causality with the WHO-UMC system. Synthesis was narrative; cohort proportions are given with Wilson 95% confidence intervals (CIs) and were not pooled, because study populations overlapped. Results: Of 590 database and register records (536 after de-duplication), eight studies met the eligibility criteria: three case reports, one case series, three retrospective cohorts and one trial-registry results record. Patient- level data were available for three men aged 36, 48 and 64 years. All were treated for AD and all had biopsy-supported plaque psoriasis; one case was new-onset (Category A) and two were relapses of previously quiescent psoriasis (Category B). Individual latencies were approximately 13, 30 and 104 weeks (median 30 weeks). Two of the three patients had previously received dupilumab, and no psoriasis was reported during that exposure. Tralokinumab was discontinued in the two patients for whom this was reported. Psoriasis improved with topical corticosteroids and calcineurin inhibitors, with methotrexate, or with upadacitinib plus topical therapy. No rechallenge was reported. In the cohort studies, psoriasis or psoriasiform eruptions were recorded in 16/769 patients (2.1%; 95% CI 1.3–3.4; mean onset 28.3 weeks) in an Italian multicentre study and in 8/169 (4.7%; 2.4–9.1) in an international cohort, and they led to discontinuation in 5/416 (1.2%; 0.5–2.8) in a second Italian cohort. In a UK series, four of 139 patients developed a psoriatic arthritis-like presentation, with skin involvement in an unspecified subset. The ECZTEND registry record listed one serious psoriasiform dermatitis among 1672 participants. Every causality assessment was rated "possible". Conclusion: Reported psoriasis and psoriasiform eruptions during tralokinumab therapy show a recurrent plaque phenotype and variable, sometimes long, latency, and they improved after withdrawal and conventional or Janus kinase inhibitor treatment. The evidence is sparse, largely uncontrolled and partly overlapping. The association should therefore be treated as a potential pathway-associated adverse event and not as an established causal effect. Prospective, phenotype-rich pharmacovigilance with histopathological confirmation is needed.

Authors

Publication Details

Journal
HAL
Published
2026-11-14
DOI
https://doi.org/10.59324/jcpmr.2026.2(6).08
Primary Topic
Psoriasis: Treatment and Pathogenesis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Tralokinumab-Associated Paradoxical Psoriasis: A Systematic Review of Clinical Phenotypes, Latency, and Treatment Outcomes

Saud Abdullah Ali Alsharif
HAL
Psoriasis: Treatment and Pathogenesis
article

Tralokinumab-Associated Paradoxical Psoriasis: A Systematic Review of Clinical Phenotypes, Latency, and Treatment Outcomes

Saud Abdullah Ali Alsharif
article en

Abstract

Background: Tralokinumab is a fully human IgG4 monoclonal antibody that neutralises interleukin (IL)-13 and is approved for moderate- to-severe atopic dermatitis (AD). Psoriasis during IL-4/IL-13 receptor blockade with dupilumab is well described. During selective IL-13 neutralisation it has been reported only sporadically, and no systematic synthesis exists. Objective: To identify and characterise all reported psoriasis and psoriasiform eruptions during tralokinumab therapy, with emphasis on clinical phenotype, latency, management, outcomes and strength of causal evidence. Methods: This review followed PRISMA 2020 and PRISMA-S. We searched Europe PMC (three strategies, one of them full-text), PubMed/MEDLINE, Crossref and ClinicalTrials.gov from inception to 30 September 2026. These searches were supplemented by forward and backward citation searching, automated full-text keyword screening of 371 open-access articles, and review of regulatory labelling. Embase, Scopus and Web of Science were not accessible. Human studies of any design reporting psoriasis or a psoriasiform eruption in tralokinumab-exposed patients were eligible. Events were classified as new-onset psoriasis (Category A), relapse or exacerbation of pre-existing psoriasis (Category B), psoriasiform eruption without confirmed psoriasis (Category C) or diagnostic uncertainty (Category D). Quality was appraised with design-specific JBI checklists, and causality with the WHO-UMC system. Synthesis was narrative; cohort proportions are given with Wilson 95% confidence intervals (CIs) and were not pooled, because study populations overlapped. Results: Of 590 database and register records (536 after de-duplication), eight studies met the eligibility criteria: three case reports, one case series, three retrospective cohorts and one trial-registry results record. Patient- level data were available for three men aged 36, 48 and 64 years. All were treated for AD and all had biopsy-supported plaque psoriasis; one case was new-onset (Category A) and two were relapses of previously quiescent psoriasis (Category B). Individual latencies were approximately 13, 30 and 104 weeks (median 30 weeks). Two of the three patients had previously received dupilumab, and no psoriasis was reported during that exposure. Tralokinumab was discontinued in the two patients for whom this was reported. Psoriasis improved with topical corticosteroids and calcineurin inhibitors, with methotrexate, or with upadacitinib plus topical therapy. No rechallenge was reported. In the cohort studies, psoriasis or psoriasiform eruptions were recorded in 16/769 patients (2.1%; 95% CI 1.3–3.4; mean onset 28.3 weeks) in an Italian multicentre study and in 8/169 (4.7%; 2.4–9.1) in an international cohort, and they led to discontinuation in 5/416 (1.2%; 0.5–2.8) in a second Italian cohort. In a UK series, four of 139 patients developed a psoriatic arthritis-like presentation, with skin involvement in an unspecified subset. The ECZTEND registry record listed one serious psoriasiform dermatitis among 1672 participants. Every causality assessment was rated "possible". Conclusion: Reported psoriasis and psoriasiform eruptions during tralokinumab therapy show a recurrent plaque phenotype and variable, sometimes long, latency, and they improved after withdrawal and conventional or Janus kinase inhibitor treatment. The evidence is sparse, largely uncontrolled and partly overlapping. The association should therefore be treated as a potential pathway-associated adverse event and not as an established causal effect. Prospective, phenotype-rich pharmacovigilance with histopathological confirmation is needed.

HALVol. 2(6)
Psoriasis: Treatment and Pathogenesis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon